Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4326281 | 0.91 | EPHB4 (0.49) | EPHB4KDRTEKMAPTMEN1 | |
| SCHEMBL4329653 | 0.90 | EPHB4 (0.56) | EPHB4KDRTEKMAPTMEN1 | |
| SCHEMBL4327879 | 0.88 | EPHB4 (0.47) | EPHB4KDRTEKMAPTMEN1 | |
| SCHEMBL4330695 | 0.84 | MAPT (0.47) | EPHB4MAPTMEN1KMT2ALMNA | |
| SCHEMBL4325178 | 0.84 | KMT2A (0.48) | EPHB4MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4330751 | 0.83 | KMT2A (0.48) | EPHB4MAPTMEN1KMT2ARAB9A | |
| SCHEMBL4332950 | 0.82 | EPHB4 (0.56) | EPHB4KDRTEKMAPTMEN1 | |
| SCHEMBL4324301 | 0.82 | MAPT (0.52) | EPHB4MAPTMEN1KMT2ALMNA | |
| SCHEMBL4321389 | 0.82 | KDR (0.48) | EPHB4KDRTEKMAPTMEN1 | |
| SCHEMBL4318928 | 0.82 | EPHB4 (0.48) | EPHB4KDRTEKMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070254889-A1 | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2007-11-01 | — | — | US | disclosed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254889-A1 | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease | APP, BACE1, IAPP | EPHB4 1668/4885KDR 4708/4885TEK 4634/4885 |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | UCK2, AXL, CHUK | EPHB4 2943/4885KDR 55/4885TEK 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.